Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study

Abstract

Objective: Rhabdomyolysis is a potentially fatal adverse reaction mostly triggered by certain medications. Few real-world studies have shown a clear association between newer-generation anti-seizure medications (ASMs) and rhabdomyolysis. We sought to quantify the risk and evaluate the clinical features and management of rhabdomyolysis associated with newer-generation ASMs.

Methods: Data were retrieved from the US FDA Adverse Event Reporting System database (FAERS) from 2018 to 2022 on newer-generation ASMs to identify rhabdomyolysis events, and disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and corresponding 95% confidence intervals (CIs). Furthermore, case reports from 2012 to 31 December 2022 on newer-generation ASMs-induced rhabdomyolysis were retrieved for retrospective analysis.

Results: A total of 1,130 rhabdomyolysis reports from the FAERS database were considered. Levetiracetam had the greatest proportion and the highest positive signal values of rhabdomyolysis. The RORs (95% CIs) for newer-generation ASMs were, in descending order, levetiracetam 8.01 (7.26–8.84), lamotrigine 3.78 (3.25–4.40), oxcarbazepine 3.47 (2.53–4.75), pregabalin 2.75 (2.43–3.12), lacosamide 1.85 (1.29–2.65), topiramate 1.64 (1.25–2.15), and gabapentin 1.32 (1.13–1.55). Twenty-six case reports showed evidence of rhabdomyolysis, and levetiracetam (65.4%) was the most frequently reported agent. The median age was 32 years; typical initial symptoms included muscle weakness (34.8%), myalgia (34.8%), backache (17.4%), fatigue (13.0%) and leg pain (8.7%). The median time to onset of rhabdomyolysis was 2 days. All cases had elevated creatine phosphokinase (CPK), and some cases were accompanied by elevated creatinine (57.1%) and myoglobinuria (53.8%). Cessation of ASMs could lead to complete clinical remission. The median time for creatine phosphokinase (CPK) normalization was 8 days.

Conclusion: This study identified 7 newer-generation ASMs with significant rhabdomyolysis reporting associations. Prescribers should be more aware of this risk and teach patients to recognize rhabdomyolysis signs/symptoms early.

Introduction

Rhabdomyolysis is an acute muscle disorder caused by a rapid breakdown of the integrity of skeletal muscle cells, accompanied by the release of electrolytes and muscle cell contents into the blood, causing cellular dysfunction (Cabral et al., 2020). Rhabdomyolysis usually results from traumatic or nontraumatic injury to skeletal muscle and can occur in all age groups and both sexes (Cervellin et al., 2017). The typical signs and symptoms of rhabdomyolysis are called the classic triad: acute or subacute myalgia, muscle weakness mostly in the proximal lower limbs and dark tea-coloured urine (Cervellin et al., 2010). However, more than 50% of patients do not have muscle pain or weakness, and fewer than 10% of patients present with a full triad (Bosch et al., 2009). Clinical manifestations vary from a subclinical elevation of serum creatine phosphokinase (CPK), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) to severe electrolyte imbalance, cardiac arrhythmia, acute renal failure and disseminated intravascular coagulation (DIC), which depend on the extent of muscle damage (Cabral et al., 2020). A survey indicated that rhabdomyolysis is at least 5 times more likely to be the result of a nontraumatic than traumatic factor (Watson et al., 2014), and drugs are one of the most common causes of rhabdomyolysis in adults. The drugs most often suspected on inducing rhabdomyolysis are statins, fibrates, psychotropic substances, antibiotics and certain herbs (Hohenegger, 2012; Torres et al., 2015). Rhabdomyolysis caused by antiepileptic drugs has become an issue in recent years, although it is still a rare event (Siniscalchi et al., 2021).

Over the past 3 decades, numerous anti-seizure medications (ASMs) with different mechanisms of action have been introduced with the aim of providing better efficacy or safety profiles than the previous drugs, and the older-generation ASMs are increasingly being replaced by the newer-generation ASMs such as levetiracetam, lamotrigine, gabapentin, oxcarbazepine, lacosamide, topiramate, and zonisamide. Research has revealed that the newer generation of ASMs have advantages in terms of drug‒drug interactions, pharmacokinetics and teratogenicity and offer valuable individualized options for the treatment of epilepsy (Chen et al., 2020). Growing evidences from case reports and reviews have suggested that these drugs are associated with rhabdomyolysis (Jiang et al., 2016). However, limited real-world data are available regarding complications related to the newer-generation ASMs-induced rhabdomyolysis, suggesting that this adverse event (AE) may be a neglected risk in therapy with these agents.

In the present study, we searched for signals in the FDA Adverse Event Reporting System (FAERS) database and described the clinical characteristics, management, and prognosis of rhabdomyolysis in patients after newer-generation ASMs therapy in real-life settings, with the goal of raising clinicians’ awareness of this adverse effect and increasing its early diagnosis.

Materials and methods

Study design

In this study, a retrospective, disproportionality, pharmacovigilance study was conducted. Data were collected from the publicly released FAERS database on the FDA website from 2018 Quarter 1 (Q1) to 2022 Q3 to assess the risk of rhabdomyolysis from different newer-generation ASMs in a large population. More recent data were chosen because the epidemiology of rhabdomyolysis is changing constantly. Duplicate reports were removed by case number, with only the most recently submitted version included. Reports containing drugs that were administered by oral, intramuscular, subcutaneous, intravenous, and parenteral routes were included, while other routes of administration were excluded.

Drug exposure and adverse drug reaction definition

The AEs of newer-generation ASMs were encoded by the preferred terms (PTs) in the Medical Dictionary for Regulatory Activities 24.0 (MedDRA). We only used the MedDRA PT “rhabdomyolysis” to identify relevant cases. Other terms, such as “myalgia” and “creatine phosphokinase increased,” were not used because these terms do not guarantee rhabdomyolysis. The newer-generation ASMs were selected from the Drugs@FDA Database and were identified by generic and brand names. Drugs are assigned a role (primary suspect, secondary suspect, concomitant, interacting) by the person reporting the adverse drug reaction (ADR). The newer-generation ASMs which fewer than three rhabdomyolysis ADR reports were excluded from the data analysis.

Pharmacovigilance study

Disproportionality analysis was employed to detect safety signals by using the reporting odds ratio (ROR). When a target drug is more likely to induce a target AE than all other drugs, it will typically obtain a higher score due to a higher disproportionality. The equations and criteria for the algorithm are shown in Supplementary Table S1. A reporting association was considered to be statistically significant if the lower limit of the 95% CI was >1.0. All data processing and statistical analyses were performed using MySQL 8.0, Navicat Premium 15, Microsoft Excel 2022, and GraphPad Prism 8 (GraphPad Software, CA, United States).

Descriptive study

A comprehensive search of multiple electronic databases, including PubMed, Embase, Wanfang, China National Knowledge Infrastructure (CNKI) and China Biology Medicine Disc (CBMdisc), from January 2012 to December 2022 regarding newer-generation ASM-induced rhabdomyolysis was conducted, with no language restrictions. The search terms were “levetiracetam,” “lamotrigine,” “pregabalin,” “gabapentin,” “lacosamide,” “topiramate,” “oxcarbazepine,” “perampanel,” “brivaracetam,” “rufinamide,” “rhabdomyolysis,” “myalgia” and “creatine phosphokinase”. We included case reports and excluded preliminary studies, mechanistic studies, animal studies, reviews, duplicate literature and articles with no available full text. Two reviewers searched the literature and collected data independently. Clinical characteristics including age, sex, region of patients, indication, medical history, time to onset, clinical manifestations, laboratory features, treatment and prognosis with newer generation induced rhabdomyolysis were collected. The time to onset of target rhabdomyolysis was defined as from the date of initiation of the antiepileptic drugs to the onset of target rhabdomyolysis data.

Results

Newer-generation ASMs-associated rhabdomyolysis in the FAERS database

From January 2018 to September 2022, a total of 261,586 newer-generation ASMs-associated AEs were recorded in the FAERS database, among which 1,142 were for rhabdomyolysis. Levetiracetam was the most reported drug in rhabdomyolysis cases (n = 421, 36.9%), followed by pregabalin (n = 255, 22.3%), lamotrigine (n = 171, 15.0%), gabapentin (n = 162, 14.2%), topiramate (n = 52, 4.6%), oxcarbazepine (n = 39, 3.4%), lacosamide (n = 30, 2.6%), perampanel (n = 4, 0.4%), zonisamide (n = 4, 0.4%), brivaracetam (n = 3, 0.3%) and rufinamide (n = 1, 0.1%). The reported clinical characteristics of the primary suspected drugs are described in Table 1.

Disproportionality analysis

Rhabdomyolysis signals for the newer-generation ASMs under the criteria of the ROR are summarized in Table 2. Seven newer-generation ASMs with 1,130 cases involved have been identified as having significant reporting associations with rhabdomyolysis. Levetiracetam had the strongest statistical association with the highest positive signal values of rhabdomyolysis, accounting for 1.14% of all levetiracetam-related reports. Rhabdomyolysis RORs (95% CI) for all newer-generation ASMs were in descending order: levetiracetam 8.01 (7.26–8.84), lamotrigine 3.78 (3.25–4.40), oxcarbazepine 3.47 (2.53–4.75), pregabalin 2.75 (2.43–3.12), lacosamide 1.85 (1.29–2.65), topiramate 1.64 (1.25–2.15), and gabapentin 1.32 (1.13–1.55) (Figure 1).

FIGURE 1

Descriptive analysis

We identified 26 case reports of rhabdomyolysis induced by newer-generation ASMs, with 26 patients included (10 males and 16 females) (Kaufman and Choy, 2012; Gunathilake et al., 2013; Akiyama et al., 2014; Isaacson et al., 2014; Spengler et al., 2014; Incecik et al., 2016; Karaoulanis et al., 2016; Kato et al., 2016; Ramon et al., 2016; Singh et al., 2016; Choi et al., 2017; Coupal et al., 2017; Di Lorenzo and Li, 2017; Kubota et al., 2017; Shahbaz et al., 2017; Matsudaira et al., 2018; Mena-Martin et al., 2018; Rastogi et al., 2018; Rota et al., 2018; Qiu et al., 2019; Thomas et al., 2019; Aslan et al., 2020; Ghosh et al., 2020; Moinuddin, 2020; Alshehabi et al., 2022; Boucher et al., 2022) (Table 3). All the studies were published in English and originated from the following regions: 10 cases from South America, 10 cases from Asia, 5 cases from Europe and 1 case from Oceania. The median age of these patients was 32 years (range 13–75 years), and the majority of patients were between 19 and 50 years old (69.2%), with 3 patients (11.6%) less than 18 years old. Among the newer-generation ASMs, levetiracetam (17 cases, 65.4%) was associated with the highest risk of rhabdomyolysis, followed by gabapentin (4 cases, 15.4%), pregabalin (3 cases, 11.6%), lamotrigine (1 case, 3.8%) and lacosamide (1 case, 3.8%). The concomitant disease was described in 6 cases, including anxiety/depression/schizophrenia (4 cases, 66.7%), hyperlipidemia (4 cases, 66.7%) and hypertension (3 cases, 50.0%). Fourteen patients were taking combinations of medications: other types of ASMs in 6 patients, anti-anxiety/anti-depression drugs in 5 patients, sedatives and hypnotics, cardiovascular drugs and analgesic drugs in 4 patients each. The median time of symptom onset was 2 days (range 1–30 days), with 10 cases (41.7%) occurring within 24 h and 6 cases (25.0%) occurring between 1 and 3 days. The Naranjo scale categorized the probability of newer-generation ASM-induced rhabdomyolysis in the 26 included studies was: 22 cases (84.6%) were classified as probable, 3 cases (11.6%) as possible, and 1 case (3.8%) as doubtful (Table 4).

Clinical symptoms were described in 23 patients. Muscle weakness (34.8%), myalgia (34.8%), backache (17.4%), fatigue (13.0%) and leg pain (8.7%) were common symptoms in patients with rhabdomyolysis, while 39.1% of the patients had no symptoms. All 26 included patients had elevated creatine phosphokinase (CPK) levels. The median CPK level was 15,461 U/L (range 747–921672 U/L), and the median peak time of CPK was 5 days (range 1–30 days) after administration of the antiepileptic drug. Elevated lactate dehydrogenase (LDH) was reported in 5 patients, with a median value of 1,172 U/L (309–2,200 U/L), and serum myoglobin was elevated in 7 patients with a median value of 228 ng/mL (78–20,000 ng/mL). Twelve patients had renal injury with significantly elevated creatinine out of the 21 patients in whom creatinine was measured (57.1%), while 42.9% had normal creatinine levels. Urine testing was reported in 13 patients, with 9 (69.2%) experiencing myoglobinuria. All 26 included patients stopped the suspected causative drug immediately after developing rhabdomyolysis, 1 of whom underwent continuous renal replacement and 2 had haemodialysis, 88.5% of whom were without further treatment, and all cases achieved resolution of symptoms and complete remission. The time to normalization of CPK was between 3 and 38 days, with 11 patients (50.0%) normalizing within 7 days and 7 patients normalizing between 8 and 14 days. The median time to normalization of CPK was 8 days (range 3–38 days) (Table 5).

Discussion

To the best of our knowledge, this is the largest real-life comparative study reporting rhabdomyolysis after treatment with newer-generation ASMs along with a supportive disproportionality analysis. We performed analysis of the last 57 months of FAERS data and identified 7 newer-generation ASMs that had significant reporting associations with rhabdomyolysis. We found that levetiracetam had the greatest proportion of rhabdomyolysis events, with the highest positive signal values. The other newer-generation ASMs with rhabdomyolysis reports included lamotrigine, oxcarbazepine, pregabalin, lacosamide, topiramate, and gabapentin. In the descriptive analysis, levetiracetam was the most frequently reported potential agent for rhabdomyolysis as well, accounting for 65.4% of all cases included. Currently, only pregabalin lists rhabdomyolysis as a possible adverse reaction in its package insert. Our findings are clinically relevant because they will be helpful to improve clinicians’ awareness, increase early diagnosis and guide clinical treatment of newer-generation ASM–induced rhabdomyolysis. In addition, we provide separate analyses of initial symptom onset, laboratory features, treatment, outcomes, and prognosis, which had not been done in previous studies. By collecting medical records from published case reports involving newer-generation ASM-associated rhabdomyolysis, we found that muscle weakness, myalgia, backache, fatigue and leg pain were the most common symptoms, which were often accompanied by elevated CPK, LDH, creatinine, and serum myoglobin. Therefore, it is recommended that patients with muscle weakness, myalgia, or pain be alerted to the possibility of rhabdomyolysis and undergo regular laboratory tests during newer-generation ASM treatment.

We observed that newer-generation ASMs can cause rhabdomyolysis early in treatment, with a median onset time of 2 days (range 1–30 days), and approximately 66.7% of the included cases occurred within 3 days, indicating that suspicious symptoms and laboratory indicators associated with rhabdomyolysis should be monitored early in treatment in particular. The timing of the onset of rhabdomyolysis varied depending on the type of medication involved. A previous post-marketing analysis from the FAERS data raised a safety signal detecting 48 reports of LEV-induced rhabdomyolysis from 2004 to 2015, which had a median time to onset of a few days (Carnovale et al., 2017). This interval is comparable to that of rhabdomyolysis induced by other drugs, such as antibiotics, particularly quinolone (Bouchard et al., 2019), but shorter than in paradoxical cases reported with statins (Vinci et al., 2021), with which it occurs within a few weeks to months. There was one report of a 36-year-old male who took levetiracetam for 2 years before rhabdomyolysis onset, whom we did not include in the calculation of the median onset time to avoid negative skewing of the results (Alshehabi et al., 2022). It should be noted that the intake of high doses of ASMs can be the cause of myotoxicity. We observed that three of the four patients on gabapentin therapy developed rhabdomyolysis immediately after the dose increased, and 2 patients exceeded the maximum dosage recommended by the package insert. Considering the limited number of cases here, the relationship between the occurrence of rhabdomyolysis and the daily dose of newer-generation ASMs needs to be further confirmed by prospective studies. In addition, we observed that 4 patients took combination therapies that may cause rhabdomyolysis, including statins (3 cases) and azithromycin (1 case) (Kato et al., 2016). Rhabdomyolysis is known to be a common adverse effect of statins. Of the three patients who took statins as concomitant therapy, two patients took statins for a longer period (Gunathilake et al., 2013; Qiu et al., 2019), and one patient developed myalgia symptoms after 4 days of statin and increased dose of gabapentin for 1 day. In this case, both statins and gabapentin may have been responsible for his rhabdomyolysis (Kaufman and Choy, 2012).

It remains difficult to demonstrate whether certain ASMs are triggering factors or happen to be present in rhabdomyolysis cases. In some cases of rhabdomyolysis, drug interactions may have played a potential role due to either altered bioavailability and/or decreased clearance (Duncan and Howden, 2017). Proton pump inhibitors (PPIs) can inhibit the cytochrome P450 enzyme system and increase the bioavailability of statins to increase the risk of statin-related rhabdomyolysis (Clark and Strandell, 2006). However, in vitro studies of pregabalin, gabapentin, and levetiracetam have shown that they do not inhibit drug metabolism and have low plasma protein binding rates, meaning they rarely interact with other drugs. Lamotrigine also showed no evident hepatic enzyme induction and had no correlation with drugs metabolized by cytochrome P450 enzymes. Therefore, we tend to believe that the newer-generation ASMs themselves act as triggering factors for rhabdomyolysis, after ruling out possible drug interactions. It is worth noting that genetic polymorphisms relevant to pharmacokinetics (e.g., in drug receptors, transporters and metabolizing enzymes) and pharmacodynamics predispose patients to myopathy. It has been validated that polymorphisms in the SLCO1B1 gene, which encodes the protein responsible for hepatic uptake of statins, and the COQ2 gene, which encodes an enzyme involved in the synthesis of coenzyme Q10, are strongly associated with statin-induced myopathy (Needham and Mastaglia, 2014). Recently, new ASMs that have been investigated in populations across the world and found to be significantly affected by metabolic enzymes and their genetic polymorphisms include lamotrigine, oxcarbazepine and levetiracetam (Zhao and Meng, 2022). Unfortunately, there is no clear evidence for the relationship between genetic polymorphisms affecting new AEDs and rhabdomyolysis. In the future, investigating genetic factors predisposing to AED-induced rhabdomyolysis might act as the first step towards pharmacogenomic screening to identify at-risk individuals.

The mechanism by which certain ASMs can cause rhabdomyolysis have not been illustrated. In recent years, some studies have used machine learning methods to establish quantitative structure-activity relationship models. Based on the chemical structure information of drugs, the model can well predict drug-induced rhabdomyolysis and its severity, which suggests that the drugs causing rhabdomyolysis might have specific chemical structure (Cui et al., 2019; Zho et al., 2021). It provides a reasonable explanation for different types of newer-generation ASM-associated rhabdomyolysis. The exploration of molecular mechanisms targeting these specific chemical structures will help us to accurately discover the pathogenesis of their muscular toxicity. As for the molecular mechanism, LEV was reported to bind specifically with the SV2A protein, which is a membrane protein specifically expressed in synaptic vesicles and causes neuronal inhibition (Tokudome et al., 2018). However, SV2A was shown to be selectively localized in motor nerve terminals on slow (type I and small type IIA) muscle fibres in mice as well. The receptor present in the muscle fibres may suggest a mechanism for LEV-induced rhabdomyolysis (Chakkalakal et al., 2010). In addition, some research suggests that ferroptosis is a key causative factor in a variety of skeletal muscle diseases, including sarcopenia, rhabdomyolysis, rhabdomyosarcoma, and exhaustive exercise-induced fatigue (Wang et al., 2022). Discovered that ferroptosis serves as a mechanism in statin-induced myopathy. Among four candidates investigated, including atorvastatin, lovastatin, rosuvastatin, and pravastatin, only atorvastatin inhibits human cardiomyocyte (HCM) and murine skeletal muscle cell (C2C12) viability in a dose-dependent manner and leads to ferroptosis in HCM and C2C12 cells (Zhang et al., 2022). As a promising treatment strategy, ferroptosis can be explored for newer-generation ASM-associated rhabdomyolysis in future research.

Optimal management of newer-generation ASM-associated rhabdomyolysis depends on the recognition and elimination of the underlying cause when identifiable. Treatment consists of discontinuing the offending agent and aggressive fluid resuscitation with isotonic saline, which aims to maximize renal perfusion and thus limit intratubular cast formation. We observed that acute kidney injury occurred in 57.1% of rhabdomyolysis patients, who had a median creatinine level of 2.2 mg/dL (range 0.7–13.4 mg/dL), and the patient who had the highest peak CPK developed the most severe AKI, with a peak creatinine level of 1,185 μmol/L (Alshehabi et al., 2022). Research has shown that the mortality rate is 42% in those who develop acute renal failure (Russell, 2005), that any delay in fluid resuscitation increases the risk of acute kidney injury (AKI), and that forced diuresis within 6 h of presentation may reduce the risk of AKI (Zager, 1996; Hebert et al., 2023). Therefore, aggressive intravenous fluid resuscitation is necessary to reduce the damaging effects or prevent a fatal outcome regardless of the presence of AKI. Generally, the prognosis mainly depends on the complications presented and their underlying causes. In our descriptive analysis, the rhabdomyolysis related to newer-generation ASMs was reversible, and the prognosis was good, all patients achieving complete clinical recovery, even those with severe AKI.

Conclusion

Our retrospective analysis identified 7 newer-generation ASMs with significant reporting associations with rhabdomyolysis: levetiracetam, lamotrigine, oxcarbazepine, pregabalin, lacosamide, topiramate and gabapentin. Physicians and clinical pharmacists should pay close attention to possible clinical symptoms such as muscle weakness, myalgia, backache and fatigue as well as rhabdomyolysis markers like elevated CPK, LDH, creatinine and serum myoglobin during newer-generation ASMs treatment to identify early warning signs and prevent any severe complications. Early evaluation and withdrawal of the offending agent immediately improved the clinical symptoms. Aggressive intravenous fluid resuscitation is necessary to reduce the damaging effects whether or not AKI had occurred. Further prospective studies evaluating risk factors for rhabdomyolysis and concomitant therapies of patients treated with newer-generation ASMs are needed to confirm our findings.

References

• 1

  AkiyamaH.HagaY.SasakiN.YanagisawaT.HasegawaY. (2014). A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy Behav. Case Rep.2, 152–155. 10.1016/j.ebcr.2014.08.001

  • CrossRef
  • Google Scholar

• 2

  AlshehabiK. M.AskandaraniS.AlkhalifahZ. A. (2022). Suspected levetiracetam-induced acute rhabdomyolysis in a patient with retinoblastoma: A case report and literature review. Cureus14, e25183. 10.7759/cureus.25183

  • CrossRef
  • Google Scholar

• 3

  AslanN.YildizdasD.HuseyinliB.HorozO. O.MertG. G.EkinciF.et al (2020). Levetiracetam treatment-associated acute rhabdomyolysis in an adolescent. J. Pediatr. Intensive Care9, 139–140. 10.1055/s-0039-1700951

  • CrossRef
  • Google Scholar

• 4

  BoschX.PochE.GrauJ. M. (2009). Rhabdomyolysis and acute kidney injury. N. Engl. J. Med.361, 62–72. 10.1056/NEJMra0801327

  • CrossRef
  • Google Scholar

• 5

  BouchardJ.De La PenaN.OleksiukL. M. (2019). Levofloxacin-induced rhabdomyolysis in a patient on concurrent atorvastatin: Case report and literature review. J. Clin. Pharm. Ther.44, 966–969. 10.1111/jcpt.13010

  • CrossRef
  • Google Scholar

• 6

  BoucherK. S.DedhiaN.BommisettyD. (2022). Levetiracetam-induced rhabdomyolysis following medication Re-initiation. Cureus14, e30042. 10.7759/cureus.30042

  • CrossRef
  • Google Scholar

• 7

  CabralB.EddingS. N.PortocarreroJ. P.LermaE. V. (2020). Rhabdomyolysis. Dis. Mon.66, 101015. 10.1016/j.disamonth.2020.101015

  • CrossRef
  • Google Scholar

• 8

  CarnovaleC.GentiliM.AntoniazziS.ClementiE.RadiceS. (2017). Levetiracetam-induced rhabdomyolysis: Analysis of reports from the food and drug administration's adverse event reporting system database. Muscle Nerve56, E176-E178–8. 10.1002/mus.25972

  • CrossRef
  • Google Scholar

• 9

  CervellinG.ComelliI.BenattiM.Sanchis-GomarF.BassiA.LippiG. (2017). Non-traumatic rhabdomyolysis: Background, laboratory features, and acute clinical management. Clin. Biochem.50, 656–662. 10.1016/j.clinbiochem.2017.02.016

  • CrossRef
  • Google Scholar

• 10

  CervellinG.ComelliI.LippiG. (2010). Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin. Chem. Lab. Med.48, 749–756. 10.1515/CCLM.2010.151

  • CrossRef
  • Google Scholar

• 11

  ChakkalakalJ. V.NishimuneH.RuasJ. L.SpiegelmanB. M.SanesJ. R. (2010). Retrograde influence of muscle fibers on their innervation revealed by a novel marker for slow motoneurons. DEVELOPMENT137, 3489–3499. 10.1242/dev.053348

  • CrossRef
  • Google Scholar

• 12

  ChenZ.BrodieM. J.KwanP. (2020). What has been the impact of new drug treatments on epilepsy?Curr. Opin. Neurol.33, 185–190. 10.1097/WCO.0000000000000803

  • CrossRef
  • Google Scholar

• 13

  ChoiM. S.JeonH.KimH. S.JangB. H.LeeY. H.ParkH. S.et al (2017). A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy. Hemodial. Int.21, E4-E8–E8. 10.1111/hdi.12458

  • CrossRef
  • Google Scholar

• 14

  ClarkD. W.StrandellJ. (2006). Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?Eur. J. Clin. Pharmacol.62, 473–479. 10.1007/s00228-006-0131-1

  • CrossRef
  • Google Scholar

• 15

  CoupalT. M.ChangD. R.PennycookeK.OuelletteH. A.MunkP. L. (2017). Radiologic findings in gabapentin-induced myositis. J. Radiol. Case Rep.11, 30–37. 10.3941/jrcr.v11i4.3092

  • CrossRef
  • Google Scholar

• 16

  CuiX.LiuJ.ZhangJ.WuQ.LiX. (2019). In silico prediction of drug-induced rhabdomyolysis with machine-learning models and structural alerts. J. Appl. Toxicol.39, 1224–1232. 10.1002/jat.3808

  • CrossRef
  • Google Scholar

• 17

  Di LorenzoR.LiY. (2017). Rhabdomyolysis associated with levetiracetam administration. Muscle Nerve56, E1-E2–E2. 10.1002/mus.25548

  • CrossRef
  • Google Scholar

• 18

  DuncanS. J.HowdenC. W. (2017). Proton pump inhibitors and risk of rhabdomyolysis. Drug Saf.40, 61–64. 10.1007/s40264-016-0473-2

  • CrossRef
  • Google Scholar

• 19

  GhoshS.VillanS.AlY. W. (2020). Gabapentin-induced myositis in a patient with spinal cord injury - a case report. Qatar Med. J.2020, 30. 10.5339/qmj.2020.30

  • CrossRef
  • Google Scholar

• 20

  GunathilakeR.BoyceL. E.KnightA. T. (2013). Pregabalin-associated rhabdomyolysis. Med. J. Aust.199, 624–625. 10.5694/mja13.10769

  • CrossRef
  • Google Scholar

• 21

  HebertJ. F.BurfeindK. G.MalinoskiD.HutchensM. P. (2023). Molecular mechanisms of rhabdomyolysis-induced kidney injury: From bench to bedside. Kidney Int. Rep.8, 17–29. 10.1016/j.ekir.2022.09.026

  • CrossRef
  • Google Scholar

• 22

  HoheneggerM. (2012). Drug induced rhabdomyolysis. Curr. Opin. Pharmacol.12, 335–339. 10.1016/j.coph.2012.04.002

  • CrossRef
  • Google Scholar

• 23

  IncecikF.HergunerO. M.BesenS.AltunbasakS. (2016). Acute rhabdomyolysis associated with levetiracetam therapy in a child. Acta Neurol. Belg116, 369–370. 10.1007/s13760-015-0542-9

  • CrossRef
  • Google Scholar

• 24

  IsaacsonJ. E.ChoeD. J.DohertyM. J. (2014). Creatine phosphokinase elevation exacerbated by levetiracetam therapy. Epilepsy Behav. Case Rep.2, 189–191. 10.1016/j.ebcr.2014.09.008

  • CrossRef
  • Google Scholar

• 25

  JiangW.WangX.ZhouS. (2016). Rhabdomyolysis induced by antiepileptic drugs: characteristics, treatment and prognosis. EXPERT Opin. DRUG Saf.15, 357–365. 10.1517/14740338.2016.1139572

  • CrossRef
  • Google Scholar

• 26

  KaraoulanisS. E.SyngelakisM.FokasK. (2016). Rhabdomyolysis after lamotrigine overdose: a case report and review of the literature. Ann. Gen. Psychiatry15, 6. 10.1186/s12991-016-0093-3

  • CrossRef
  • Google Scholar

• 27

  KatoK.IwasakiY.OnoderaK.HiguchiM.KatoY.et al (2016). Pregabalin- and azithromycin-induced rhabdomyolysis with purpura: An unrecognized interaction: a case report. Int. J. Surg. Case Rep.26, 221–223. 10.1016/j.ijscr.2016.07.007

  • CrossRef
  • Google Scholar

• 28

  KaufmanM. B.ChoyM. (2012). Pregabalin and simvastatin: first report of a case of rhabdomyolysis. P T37, 579–595.

  • Google Scholar

• 29

  KubotaK.YamamotoT.KawamotoM.et al (2017). Levetiracetam-induced rhabdomyolysis: A case report and literature review. Neurol. Asia22 (3), 275–278.

  • Google Scholar

• 30

  MatsudairaT.TeradaT.ArakiY.IkedaH.ObiT.InoueY. (2018). HyperCKemia associated with lacosamide therapy in an elderly patient with focal onset epilepsy. Seizure63, 14–16. 10.1016/j.seizure.2018.10.005

  • CrossRef
  • Google Scholar

• 31

  Mena-MartinF.Gutierrez-GarciaA.Martin-EscuderoJ.Fernandez-ArconadaO. (2018). Acute kidney injury and creatine kinase elevation after beginning treatment with levetiracetam. Eur. Neurol. Rev.13, 113. 10.17925/enr.2018.13.2.113

  • CrossRef
  • Google Scholar

• 32

  MoinuddinI. A. (2020). Suspected levetiracetam-induced rhabdomyolysis: A case report and literature review. Am. J. Case Rep.21, e926064. 10.12659/AJCR.926064

  • CrossRef
  • Google Scholar

• 33

  NeedhamM.MastagliaF. L. (2014). Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul. Disord.24, 4–15. 10.1016/j.nmd.2013.09.011

  • CrossRef
  • Google Scholar

• 34

  QiuX.TackettE.KhitanZ. (2019). A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy. Clin. Case Rep.7, 1596–1599. 10.1002/ccr3.2302

  • CrossRef
  • Google Scholar

• 35

  RamonM.TourteauE.LemaireN.GautierS.BeneJ. (2016). HyperCKemia induced by levetiracetam. PRESSE Med.45, 943–944. 10.1016/j.lpm.2016.05.014

  • CrossRef
  • Google Scholar

• 36

  RastogiV.SinghD.KaurB.AroraP.GadikotaJ. P. (2018). Rhabdomyolysis: A rare adverse effect of levetiracetam. Cureus10, e2705. 10.7759/cureus.2705

  • CrossRef
  • Google Scholar

• 37

  RotaE.ArenaL.CelliL.TestaL.MorelliN. (2018). Levetiracetam-induced rhabdomyolysis: the first Italian case. Neurol. Sci.39, 1629–1630. 10.1007/s10072-018-3421-3

  • CrossRef
  • Google Scholar

• 38

  RussellT. A. (2005). Acute renal failure related to rhabdomyolysis: pathophysiology, diagnosis, and collaborative management. Nephrol. Nurs. J.32 (409-17), 409–417.

  • Google Scholar

• 39

  ShahbazN.YounusS. M.KhanS. A.AinQ.KhanM. A.MemonM. H. (2017). Levetiracetam induced increase in creatine phosphokinase levels. J. Coll. Physicians Surg. Pak27, S63-S64.

  • Google Scholar

• 40

  SinghR.PatelD. R.PejkaS. (2016). Rhabdomyolysis in a hospitalized 16-year-old boy: A rarely reported underlying cause. Case Rep. Pediatr.2016, 7873813. 10.1155/2016/7873813

  • CrossRef
  • Google Scholar

• 41

  SiniscalchiA.MintzerS.De SarroG.GallelliL. (2021). Myotoxicity induced by antiepileptic drugs: Could be a rare but serious adverse event?Psychopharmacol. Bull.51, 105–116.

  • Google Scholar

• 42

  SpenglerD. C.MontourisG. D.HohlerA. D. (2014). Levetiracetam as a possible contributor to acute kidney injury. Clin. Ther.36, 1303–1306. 10.1016/j.clinthera.2014.06.002

  • CrossRef
  • Google Scholar

• 43

  ThomasL.MirzaM.ShaikhN. A.AhmedN. (2019). Rhabdomyolysis: a rare adverse effect of levetiracetam. BMJ Case Rep.12, e230851. 10.1136/bcr-2019-230851

  • CrossRef
  • Google Scholar

• 44

  TokudomeK.ShimizuS.SerikawaT.OhnoY. (2018). Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy. Nihon Yakurigaku Zasshi152, 275–280. 10.1254/fpj.152.275

  • CrossRef
  • Google Scholar

• 45

  TorresP. A.HelmstetterJ. A.KayeA. M.KayeA. D. (2015). Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J.15, 58–69.

  • Google Scholar

• 46

  VinciP.PanizonE.TosoniL. M.CerratoC.PellicoriF.MearelliF.et al (2021). Statin-associated myopathy: Emphasis on mechanisms and targeted therapy. Int. J. Mol. Sci.22, 11687. 10.3390/ijms222111687

  • CrossRef
  • Google Scholar

• 47

  WangY.ZhangZ.JiaoW.WangX.ZhaoY.et al (2022). Ferroptosis and its role in skeletal muscle diseases. Front. Mol. Biosci.9, 1051866. 10.3389/fmolb.2022.1051866

  • CrossRef
  • Google Scholar

• 48

  WatsonJ. D.GiffordS. M.ClouseW. D. (2014). Biochemical markers of acute limb ischemia, rhabdomyolysis, and impact on limb salvage. Semin. Vasc. Surg.27, 176–181. 10.1053/j.semvascsurg.2015.01.007

  • CrossRef
  • Google Scholar

• 49

  ZagerR. A. (1996). Rhabdomyolysis and myohemoglobinuric acute renal failure. KIDNEY Int.49, 314–326. 10.1038/ki.1996.48

  • CrossRef
  • Google Scholar

• 50

  ZhangQ.QuH.ChenY.LuoX.ChenC.XiaoB.et al (2022). Atorvastatin induces mitochondria-dependent ferroptosis via the modulation of nrf2-xCT/GPx4 Axis. Front. Cell Dev. Biol.10, 806081. 10.3389/fcell.2022.806081

  • CrossRef
  • Google Scholar

• 51

  ZhaoW.MengH. (2022). Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population. BIOENGINEERED13, 7709–7745. 10.1080/21655979.2022.2036916

  • CrossRef
  • Google Scholar

• 52

  ZhouY.LiS.ZhaoY.GuoM.LiuY.LiM.et al (2021). Quantitative structure-activity relationship (QSAR) model for the severity prediction of drug-induced rhabdomyolysis by using random forest. Chem. Res. Toxicol.34, 514–521. 10.1021/acs.chemrestox.0c00347

  • CrossRef
  • Google Scholar